TP53 abnormalities in MM patients are associated with refractory disease and worse outcomes, especially in the cohort harboring biallelic events, double hits with concurrent del17p and mutations, which represents a clinical challenge.16 The gene discussed is TP53; the disease is Miyoshi myopathy.